Compare VanEck Junior Gold Miners (GDXJ) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Heron Therapeutics Inc — how do they compare? VanEck Junior Gold Miners trades at $114.43 (market cap $8.22B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: VanEck Junior Gold Miners is far larger — about 120.9× Heron Therapeutics Inc's market cap, and VanEck Junior Gold Miners is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Heron Therapeutics Inc for 35 Days on average.
| GDXJ | HRTX | |
|---|---|---|
Market Cap | $8.22B | $68.01M |
Volume | 3,212,198 | 1,891,941 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $1.49 |
52-Week Low | $87.56 | $0.27 |
Typical Hold Time | 41 Days | 35 Days |
Enterprise Value | — | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $110.91, up 1.62% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Recent news highlights multiple junior gold mining companies being added to the ETF, potentially increasing its diversification and appeal. Key financial ratios are not applicable as this is an ETF tracking an index of companies.
The outlook for GDXJ is influenced by gold price volatility and the performance of its underlying junior mining holdings. Opportunities exist if gold prices rise, boosting miner profitability, but risks include operational challenges and market sentiment shifts. Investors should weigh exposure to small-cap miners against broader market conditions.
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
